Your browser doesn't support javascript.
loading
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Konstantinopoulos, Panagiotis A; Waggoner, Steven; Vidal, Gregory A; Mita, Monica; Moroney, John W; Holloway, Robert; Van Le, Linda; Sachdev, Jasgit C; Chapman-Davis, Eloise; Colon-Otero, Gerardo; Penson, Richard T; Matulonis, Ursula A; Kim, Young Bae; Moore, Kathleen N; Swisher, Elizabeth M; Färkkilä, Anniina; D'Andrea, Alan; Stringer-Reasor, Erica; Wang, Jing; Buerstatte, Nathan; Arora, Sujata; Graham, Julie R; Bobilev, Dmitri; Dezube, Bruce J; Munster, Pamela.
Afiliação
  • Konstantinopoulos PA; Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Waggoner S; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Vidal GA; Department of Reproductive Medicine, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, Ohio.
  • Mita M; Division of Medical Oncology, West Cancer Center, Memphis, Tennessee.
  • Moroney JW; Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
  • Holloway R; Section of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, Illinois.
  • Van Le L; Division of Gynecologic Oncology, Florida Hospital Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando.
  • Sachdev JC; Global Robotics Institute, Orlando, Florida.
  • Chapman-Davis E; Department of Obstetrics & Gynecology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill.
  • Colon-Otero G; Division of Hematology and Oncology, Virginia G. Piper Cancer Center Clinical Trials, HonorHealth Research Institute, Scottsdale, Arizona.
  • Penson RT; Translational Genomics Research Institute, Scottsdale, Arizona.
  • Matulonis UA; Weill Cornell Medicine, Department of Obstetrics and Gynecology, Cornell University, New York, New York.
  • Kim YB; Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida.
  • Moore KN; Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston.
  • Swisher EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Färkkilä A; Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts.
  • D'Andrea A; Stephenson Cancer Center, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City.
  • Stringer-Reasor E; Sarah Cannon Research Institute, Nashville, Tennessee.
  • Wang J; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle.
  • Buerstatte N; Department of Obstetrics and Gynaecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Arora S; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Graham JR; Division of Hematology/Oncology, Department of Medicine, The University of Alabama at Birmingham.
  • Bobilev D; Department of Research & Early Development, TESARO: A GSK Company, Waltham, Massachusetts.
  • Dezube BJ; Department of Clinical Operations, TESARO: A GSK Company, Waltham, Massachusetts.
  • Munster P; Department of Biostatistics, TESARO: A GSK Company, Waltham, Massachusetts.
JAMA Oncol ; 5(8): 1141-1149, 2019 Aug 01.
Article em En | MEDLINE | ID: mdl-31194228
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article